Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Amphastar Pharmaceuticals ( (AMPH) ).
On October 21, 2025, Amphastar Pharmaceuticals entered into a Distribution Agreement with Nanjing Chengong Pharmaceutical to expand the distribution of its nasal powder product, BAQSIMI®, in Mainland China, Taiwan, Hong Kong, and Macau. This agreement, which includes profit sharing and regulatory responsibilities for Chengong, represents a related party transaction due to shared ownership interests, and was approved by Amphastar’s Audit Committee.
The most recent analyst rating on (AMPH) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock, see the AMPH Stock Forecast page.
Spark’s Take on AMPH Stock
According to Spark, TipRanks’ AI Analyst, AMPH is a Neutral.
Amphastar Pharmaceuticals’ overall stock score is driven by its strong valuation and financial stability, despite challenges in revenue growth and cash flow. The technical analysis indicates a bearish trend, but the stock’s undervaluation presents potential upside. The earnings call provided mixed signals, with strategic expansions and product successes offset by competitive pressures and declining revenues.
To see Spark’s full report on AMPH stock, click here.
More about Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. is a pharmaceutical company involved in the production and distribution of nasal powder products, with a focus on expanding its market presence in the Greater China region.
Average Trading Volume: 492,743
Technical Sentiment Signal: Sell
Current Market Cap: $1.14B
For detailed information about AMPH stock, go to TipRanks’ Stock Analysis page.